Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Artificial Intelligence (AI) can drive cars, beat humans at their own games and transcribe speech. Biology and medicine present much greater challenges, but the recent exponential growth in biomedical data has made AI assisted drug development a reality. Brendan Frey, a pioneer in this field, will discuss how Deep Genomics is using AI for target discovery and drug development, and give his perspective on the opportunities and challenges that lie ahead,
such as guaranteeing prediction accuracy and establishing trust with clinicians and regulators.
Targeted Delivery of Oligonucleotides to Muscle with Antibody Oligo conjugates.
Avidity Biosciences has developed novel technology for delivering oligonucleotide payloads to multiple tissues using antibody oligonucleotide conjugates (AOCs). This presentation will focus on recent data demonstrating pharmacologic activity of payloads to muscle for the treatment of rare muscle diseases. The properties of these AOCs make them attractive therapeutic agents. With this application, oligonucleotide agents can be delivered to multiple target sites. The technology has now been demonstrated with multiple payloads in multiple species.